Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size

Hemodialysis International

Volumn 15, Issue 1, 2011, Pages 69-78

  Vulpio, Carlo ^a   Maresca, Giulia ^b   Distasio, Enrico ^c   Cacaci, Silvia ^b   Panocchia, Nicola ^a   Luciani, Giovanna ^a   Bossola, Maurizio ^a  

^a Istituto Clinica Chirurgica   (Italy)

^b Istituto di Radiologia   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Calcitriol; Hemodialysis; Parathyroid hormone; Paricalcitol; Secondary hyperparathyroidism; Ultrasonography

Indexed keywords

CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; BONE DENSITY CONSERVATION AGENT; ERGOCALCIFEROL;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEMODIALYSIS PATIENT; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; MALE; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; ANATOMY AND HISTOLOGY; COMPLICATION; HEMODIALYSIS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID GLANDS; RENAL DIALYSIS;

EID: 79251571460     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00514.x     Document Type: Article

References (31)

1. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of refractory hyperparathyroidism. Kidney Int. 2002; 61:155-160.
2. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol. 2003; 23:369-379.
3. Slatopolsky E, Dusso A, Brown AJ. Control of uremic bone disease: Role of vitamin D analogs. Kidney Int. 2002; 61:S143-S148.
4. Brancaccio D, Bommer J, Coyne D, Vitamin D. Receptor activator selectivity in the treatment of secondary hyperparathyroidism: Understanding the differences among therapies. Drugs. 2007; 67:1981-1998.
5. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994; 46:1160-1166.
6. Martin KJ, González E, Lindberg JS, et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: A double-blinded, multicenter, randomized study. Am J kidney Dis. 2001; 38:S57-S63.
7. Slatopolsky E, Finch J, Ritter C, Takahashi F. Effects of 19-nor-1, 25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis. 1998; 32:S40-S47.
8. Lund RJ, Andress DL, Amdahl M, Williams LA, Heaney RP. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol. 2010; 31:165-170.
9. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349:446-456.
10. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004; 19:1174-1181.
11. Llach FL, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis. 2001; 38:S45-S50.
12. Lindberg J, Martin KJ, González EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol. 2001; 56:315-323.
13. Sprague SM, Lerma E, McCormmick D, Abraham M, Battle D. Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001; 83:S51-S56.
14. Sprague SM, Llach F, Amdahl M, Taccetta C, Battle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63:1483-1490.
15. Fukagawa M, Kitaoka M, Yi H, et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994; 68:221-228.
16. Indridason OS, Heath H. III, Khosla S, Yohay DA, Quarles LD. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int. 1996; 50:1663-1671.
17. Katoh N, Nakayama M, Shigematsu T, et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulse-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis. 2000; 35:465-468.
18. Malberti F, Farina M, Imbasciati E. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant. 1999; 14:2398-2406.
19. Vulpio C, Bossola M, De Gaetano A, et al. Ultrasound patterns of parathyroid glands in chronic hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2008; 28:589-597.
20. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993; 92:1436-1443.
21. Matsuoka S, Tominaga Y, Sato T, et al. Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism. Ther Apher Dial. 2008; 12:391-395.
22. Okuno S, Ishimura E, Kitatani K, et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2003; 18:2613-2621.
23. Tominaga Y, Inaguma D, Matsuoka S, et al. PTG study group is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial. 2006; 10:198-204.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42:S1-S202.
25. Mittmann N, Khanna R, Rani R, Cattopadhyay J, Avram MM. Paricalcitol therapy for secondary hyperparathyroidism in patients on hemodialysis previously treated with calcitriol: A single-center crossover study. Kidney Int. 2006; 70:S64-S67.
26. Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol. 2009; 22:59-68.
27. Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol. 2006; 21:1434-1439.
28. Mitsopoulos E, Zanos S, Ginikopoulou E, Kyriklidou P, Meimaridou D, Sakellariou G. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 2006; 48:114-121.
29. Taniguchi M, Takumoto M, Tsuruya K, Hirakata H, Iida M. Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant. 2008; 4:1-8.
30. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994; 45:1710-1721.
31. Vulpio C, Bossola M, De Gaetano A., et al. Usefulness of the combination of ultrasonography and 99mTc-sestamibi scintigraphy in the preoperative evaluation of uremic secondary hyperparathyroidism. Head Neck. 2010; 32:1226-1235.